Skip to main content

Table 2 Predictive factors for DAS28(ESR) <2.6 at week 12 identified by univariate and multivariate logistic regression analysis

From: Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

 

Univariate analysis

Multivariate analysis

Odds ratio (95% CI)

P value

Odds ratio (95% CI)

P value

Age

0.99 (0.95–1.02)

0.41

  

RA duration

1.00 (0.99–1.00)

0.37

  

MTX dose

1.07 (0.94–1.238)

0.30

  

DAS28(ESR)

0.50 (0.31–0.75)

<0.001

0.67 (0.40–1.06)

0.09

HAQ-DI

0.69 (0.36–1.29)

0.25

  

EQ-5D

41.89 (1.88–1496.64)

0.02

1.66 (0.01–287.19)

0.83

CRP

0.88 (0.73–1.03)

0.12

  

RF

1.00 (0.99–1.00)

0.50

  

ACPA

1.00 (0.99–1.00)

0.30

  

MMP-3

1.00 (0.99–1.00)

0.69

  

TNFα

1.18 (0.98–1.72)

0.09

  

IL-6

1.00 (0.99–1.01)

0.46

  

HAQ-DI at 24 h

0.53 (0.25–1.04)

0.07

  

EQ-5D at 24 h

123.61 (4.82–5356.39)

<0.001

26.33 (0.514–7838.05)

0.09

CRP at 24 h

0.85 (0.66–1.02)

0.08

  

CRP at 48 h

0.77 (0.53–1.02)

0.07

  

TNFα at 24 h

0.20 (0.05–0.55)

<0.001

0.01 (0.04e−2–0.22)

<0.01

TNFα at 48 h

0.01 (2.636e-5–0.54)

<0.001

9.26 (0.30–342.47)

0.20

IL-6 at 24 h

0.98 (0.95–0.99)

0.03

1.00 (0.97–1.01)

0.92

IL-6 at 48 h

0.04 (0.01–0.60)

0.02

0.97 (0.92–1.03)

0.27

CZP at 24 h

15.56 (1.95–154.84)

<0.001

1.00 (0.99–1.01)

0.33

CZP at 48 h

16.76 (1.82–190.40)

0.01

1.00 (0.99–1.01)

0.24

  1. RA rheumatoid arthritis, MTX methotrexate, DAS disease activity score, HAQ-DI health assessment questionnaire disability index, EQ-5D EuroQol 5 Dimension, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, TNFα tumor necrosis factor, IL-6 interleukin-6, CZP cerolizumab pegol